Presently Pending Claims

*(Amendments **highlighted in bold**, language to be added underlined, language to be deleted ~~stricken through~~.)*

1. (Amended) A compound of the formula:



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

Ar^1 is aryl;

Ar^2 is aryl;

Ar^3 is arylene;

said Ar^1, **Ar^2 and Ar^3 groups possessing** ~~possesses~~ 0 to 3 substituents independently selected from the group consisting of -(C_1-C_6)alkyl, -(C_3-C_7)cycloalkyl, halo, -CN, -(C_1-C_6)alkoxy, -CF_3, -OCF_3, -$CONH_2$, -$CONH(C_1$-$C_6)$alkyl, -$CON(C_1$-$C_6)$alkyl (C_1-C_6)alkyl, -NH_2, -$NHC(O)(C_1$-$C_6)$alkyl, -$NHSO_2(C_1$-$C_6)$alkyl, -$S(C_1$-$C_6)$alkyl, -$SO(C_1$-$C_6)$alkyl, -$SO_2(C_1$-$C_6)$alkyl, methylenedioxy and NO_2;

X is O;

Y is a single bond or a -(C_1-C_4)alkylene- group;

R^1 is





R^2 is H or -(C_1-C_6)alkyl;

R^3 is independently H, or nonsubstituted or halosubstituted -(C_1-C_6)alkyl, -(C_3-C_7)cycloalkyl, -(C_3-C_7)cycloalkyl(C_1-C_6)alkyl, -(C_1-C_6)alkoxy, -(C_1-C_6)alkoxy (C_1-C_6)alkylene, aryl, -aralkyl or -heteroaralkyl;

R^4 is H, nonsubstituted or halosubstituted -(C_1-C_6)alkyl, -NH(C_1-C_6)alkyl, -NHaryl, aryl; or alkoxy or hydroxy substituted alkyl~~, and~~

~~R^5 is independently H, or nonsubstituted or halosubstituted -(C_1-C_6)alkyl, -(C_3-C_7)cycloalkyl, -(C_3-C_7)cycloalkyl(C_1-C_6)alkyl, aryl, -aralkyl, -heteroaralkyl, -(C_1-C_6)alkoxy or -(C_1-C_6)alkylene(C_1-C_6)alkoxy~~.

2. (Previously Presented) A compound as defined in Claim 1;

or a pharmaceutically acceptable addition salt and or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar^1 and Ar^2 are independently phenyl or pyridyl,

Ar^3 is 1, 4-arylene,

R^1 is  in which R^3 is -(C_1-C_6)alkyl, -(C_3-C_7)cycloalkylmethyl, (C_1-C_6)alkoxy- or (C_1-C_6)alkoxy(C_1-C_6)alkylene-,

R^2 is H,

X is O; and

Y is a single bond or -(C_1-C_3)alkylene.

3. (Canceled)

4. (Previously Presented) A compound as defined in Claim 1

or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar^1 and Ar^2 are independently phenyl or pyridyl,

Ar^3 is 1,4-arylene,

R^1 is selected from



X is O; and

Y is -(C_2-C_3)alkylene.

5. (Original) A compound as defined in Claim 2

or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar^1 is 3-substituted phenyl or pyridyl,

Ar^2 is halo-substituted or CF_3-substituted phenyl or pyridyl and

R^3 is methyl, ethyl, propyl, $-CH_2CH_2CF_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl.

6. (Original) A compound as defined in Claim 5 wherein the 3-substituent on the phenyl or pyridyl is – CN, $-OCF_3$ or chloro.

7. (Amended) A compound as defined in Claim <u>1</u> ~~3~~ wherein Ar^1 is 3-substituted phenyl or pyridyl, Ar^2 is halo-substituted or CF_3-substituted phenyl or pyridyl ~~and R^5 is methyl, ethyl, propyl, $-CH_2CH_2CF_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl~~.

8. (Original) A compound as defined in Claim 7 wherein the 3- substituent on the phenyl or pyridyl is -CN, $-OCF_3$ or chloro.

9. (Amended) A compound as defined in Claim 4 wherein Ar^1 is 3-substituted phenyl or pyridyl, Ar^2 is halo-substituted or CF_3-substituted phenyl or pyridyl ~~and R^6 is methyl, ethyl, propyl, $-CH_2CH_2CF_3$, cyclopentyl, cyclopropylmethyl or 3-methoxyethyl~~.

10. (Original) A compound as defined in Claim 9 wherein the 3- substituent on the phenyl or pyridyl is –CN, $-OCF_3$ or chloro.

11. (Amended) A compound as defined in Claim 1 selected from the group consisting of

In re Application of: Anan Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001



In re Application of: Ana[illegible]i Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001



In re Application of: Ana n Palani et al.
Serial No.: 09/995,949
Filed: 11/28/2001







12. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

13. (Original) A method of treating a metabolic disorder, eating disorder or diabetes in a subject in need thereof which comprises administering to said subject an effective amount of a compound as defined in claim 1.

14. (Original) A pharmaceutical composition which comprises an effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier thereof.

15. (Original) A method of treating eating disorders in a subject in need of such treatment which comprises administering to said subject a therapeutically effective amount of a compound of claim 1 or a pro-drug thereof or a pharmaceutically acceptable salt of said compound or of said pro-drug.

16. (Original) The method of claim 15 wherein said eating disorder is hyperphagia.

17. (Original) The method of claim 13 wherein said metabolic disorder is obesity.

18. (Original) A method of treating disorders associated with obesity in a subject in need of such treatment which comprises administering to said subject a therapeutically effective amount of a compound of claim 1 or a pro-drug thereof or a pharmaceutically acceptable salt of said compound or of said pro-drug.

19. (Original) The method of claim 18 wherein said disorders associated with obesity are type II diabetes, insulin resistance, hyperlipidemia and hypertension.

20. (Original) A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an antiobesity and/or anorectic agent such as a β_3 agonist, a thryomimetic agent, an anorectic agent or an NPY antagonist; and

a pharmaceutically acceptable carrier thereof.

21. (Original) A method of treating an eating disorder which comprises administering to a subject in need of such treatment

an amount of a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an antiobesity and/or anorectic agent such as a β_3 agonist, a thryomimetic agent, an anorectic agent or an NPY antagonist;

wherein the amounts of the first and second compounds result in a therapeutic effect.

22. (Original) A pharmaceutical composition which comprises a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a pro-drug thereof, or a pharmaceutically acceptable salt of said compound or of said pro-drug;

a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease inhibitor, insulin (including orally bioavailable insulin preparations), an insulin mimetic, metformin, acarbose, a PPAR-gamma ligand such as troglitazone, rosaglitazone, pioglitazone, or GW-1929, a sulfonylurea, glipazide, glyburide, or chlorpropamide; and a pharmaceutically acceptable carrier therefor.

23. (Original) A pharmaceutical composition made by combining the compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

24. (Original) A process for making a pharmaceutical composition comprising combining a compound as defined in claim 1 and a pharmaceutically acceptable carrier.